Fresenius Proactively Migrates to Salesforce as Veeva Split Looms
Life sciences companies are facing a significant shift as the partnership between Veeva Systems and Salesforce comes to an end by 2029. This change requires businesses to migrate to one of the platforms, prompting a strategic review of customer relationship management (CRM) strategies to maintain a competitive edge and operational continuity.
Fresenius, a global healthcare group, is proactively addressing this transition through its 'PULSE' transformation program. The company is migrating to the Salesforce Life Sciences Cloud, aiming to standardize commercial processes globally by 2029. Capgemini is partnering with Fresenius and Salesforce to define, develop, and implement the new CRM solution, covering Pharma, BioPharma, Nutrition & MedTech business units.
To support this global transformation, Fresenius has selected FIEGE as a strategic partner alongside Capgemini. The new CRM solution will manage the entire commercial lifecycle, ensuring standardized processes and regulatory compliance worldwide. This move aligns with the growing demand for next-generation CRM platforms that offer a unified digital foundation, a 360-degree customer view, and support for personalized treatments and value-based care.
As the Veeva-Salesforce split approaches, life sciences companies must reassess their CRM strategies to stay competitive and avoid disruptions. Fresenius' proactive approach, in partnership with Capgemini and FIEGE, demonstrates a commitment to leveraging modern CRM technology and partnerships to strengthen customer engagement, drive growth, and enable precise decision-making in the dynamic life sciences landscape.
